David Moskowitz

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA.

Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT.

Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA.

Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA.

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.

INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ.

Archangel Investors Ltd. is a Private Equity firm, a subsidiary of Riverside Global Partners LLC founded in 1988 by Michael David Rutterford and Barry Edward Sealey. The firm is headquartered in Boston.

CDI Bioscience, Inc. has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from explicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. The current design of the technology can be readily translated to bacterial and yeast cellular systems for the production of commercial grade bio products. Recombinant therapeutic proteins have proven to be invaluable biopharmaceuticals for the treatment of chronic and life-threatening diseases. While exceptionally effective, the dosage requirements are generally very high for the required treatment. Several hundred milligrams of protein per administration is common and multiple doses are often required and being protein based drugs, they can only be produced by living cells which is why increasing production yield is a challenge. CDI Bioscience has developed a patented technology that dramatically improves the product yield in biopharmaceutical manufacturing. CDI's core technology, RP Shift®, solves a number of intermediate problems in the development of biopharmaceutical products by significantly boosting the productivity and viability of production cells.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Genetic Alliance, Inc. provides health care services through genetics. Its customers include parent and family groups, community organizations, professional societies, corporations, and government agencies. The company was founded by Joan O. Weiss in 1986 and is headquartered in Washington, DC.

Inomax LLC is an American venture capital company.

Part of General Electric Co., Datex-Ohmeda, Inc. develops and manufactures medical equipment. The company is based in Madison, WI.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.

The Capital Network, Inc. is a private company based in Wellesley, MA that provides founder-focused fundraising education programs. The company aims to create a more inclusive and accessible funding ecosystem to support female and other first-time founders of early stage startups. The company offers three programs: the Fellowship for Female Founders, Fundraising Readiness Workshops, and the Investment and Inclusion Series. The Fellowship for Female Founders is a six-month program that has helped over 90+ female founders raise over $85m in capital. The company also offers ongoing workshops for first-time startup founders and a series of honest conversations to bring about meaningful systemic change. The Capital Network has a network of 300+ investors and sponsors who help them make the fundraising ecosystem work for everybody. The company was founded by Ashkan Afkhami and Chula Reynolds.

Cellular Research, Inc. operates as a biotechnology research and development company. It offer Precise assays that provides quantitation of mRNA targets in single cells and small samples; precise predefined gene expression panels; and Pixel system, a detection platform for direct mRNA quantitation from single cells and rare samples. The company’s products are used in various applications that include gene expression validation, RNA-seq validation, pathway validation, and rare transcript detection. The company was founded by Stephen P. A. Fodor, Ari Chaney, Stephen R. Quake and Glenn Fu in 2011 and is headquartered in Menlo Park, CA.

Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California.

Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA.

Blue Mesa Health, Inc. engages in the provision of digital therapeutics program to support the prevention diabetes and other chronic diseases. The company was founded by Misa Nuccio, Curtis Duggan, Evan Willms, Mike Benna, Jonathan Bixby, and Joshua Bixby in 2015 and is headquartered in New York, NY.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist.

Larkspur Biosciences, Inc. is a company based in Watertown, MA that is pioneering a new wave in cancer therapy. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. Larkx, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. The company was founded by Nathanael S. Gray, Vijay Kumar Kuchroo, and Lewis Clayton Cantley. The CEO is Catherine Sabatos-Peyton.